At Google I/O, CEO Demis Hassabis signaled a major shift in Google's AI-driven science strategy, highlighting a move from specialized tools to general-purpose agentic systems. Notably, the company is investing more in large language model-based 'AI Co-Scientist' agents, suggesting a broader trend within the industry.
Researchers are leveraging AI tools such as AlphaFold and BaktFold to investigate the CovR/S two-component system, a key virulence regulator in Streptococcus pyogenes. Using machine learning-based annotation and structure prediction, the study demonstrates how emerging AI methods can advance understanding of bacterial mechanisms and accelerate bioinformatics workflows.
Isomorphic Labs has announced a $2.1 billion Series B funding round to accelerate its AI-driven drug discovery initiatives. The financing, led by Thrive Capital and supported by Alphabet and other major investors, will be used to enhance the company’s drug design platform and expand its research into treatments for cancer and immune disorders.
Google DeepMind’s AlphaFold Protein Database now supports over 3 million researchers in 190 countries, providing free access to structural data for nearly all known proteins. This milestone underscores the database's expanding role in global scientific collaboration and its applications in healthcare and agricultural research.
Stay informed with curated insights delivered weekly to your inbox.